Verastem, Inc. (LON: 0LOV)
London
· Delayed Price · Currency is GBP · Price in USD
6.11
+0.00 (0.06%)
At close: Jan 31, 2025
Verastem Employees
Verastem had 73 employees as of December 31, 2023. The number of employees increased by 16 or 28.07% compared to the previous year.
Employees
73
Change (1Y)
16
Growth (1Y)
28.07%
Revenue / Employee
102.21K GBP
Profits / Employee
-955.15K GBP
Market Cap
224.63M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
ConvaTec Group | 10,136 |
Hikma Pharmaceuticals | 9,100 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Verastem News
- 4 days ago - Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference - Business Wire
- 10 days ago - Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
- 18 days ago - Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - Business Wire
- 19 days ago - Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire
- 20 days ago - Verastem Oncology announces debt refinancing with Oberland Capital - Seeking Alpha
- 20 days ago - Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - Business Wire
- 25 days ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Verastem: Planning The PDUFA Run-Up - Seeking Alpha